Alcon (ALC) Q3 2024 earnings summary

Executive summary

• Q3 2024 net sales reached $2.43 billion, up 6% year-over-year, with EPS of $0.81, a 25% increase, and a core operating margin of 20.6%.

• Free cash flow for the first nine months hit a record $1.3 billion, more than doubling from $592 million in 2023, driven by operational excellence and innovation.

• Product launches and pipeline advancements, including Precision 7 contact lenses and Systane Pro, are expected to drive future growth.

• International markets, especially China, contributed significantly to growth, offsetting softer U.S. conditions.

• Core (non-IFRS) results showed double-digit growth in operating income and net income, with core operating margin up to 20.8% for the nine months.

Financial highlights

• Q3 net sales: $2.43 billion (+6%); nine months: $7.36 billion (+5%).

• Q3 operating margin: 13.6% (up 90 bps); core operating margin: 20.6% (up 110–120 bps); nine months core margin: 20.8%.

• Q3 diluted EPS: $0.53 (+29%); core diluted EPS: $0.81 (+23–25%); nine months: $1.48 (+33–35%).

• Free cash flow for nine months: $1.3 billion, up from $592 million.

• Debt at $4.7 billion with no financial covenants; net debt reduced to $3.0 billion.

Outlook and guidance

• Full-year revenue guidance updated to $9.8–$9.9 billion, with constant currency sales growth of 6%–7%.

• Core R&D expense expected at the high end of 7%–9% of sales; core operating margin guidance tightened to 20.5%–21%.

• Core diluted EPS guidance narrowed to $3.00–$3.05, reflecting 15%–17% constant currency growth.

• Assumes market growth in line with recent quarters and stable FX rates through year-end.

• FX headwinds of $0.08 absorbed versus earlier guidance.